Skip to main content

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and rare metabolic conditions. The company advances clinical pipeline candidates targeting neurodegenerative conditions, metabolic diseases, and endocrine disorders. Principal revenues were historically generated through commercial sales of Relyvrio alongside research partnerships, licensing options, and development capital financing. Core end markets serve neurology clinical centers, neurodegenerative research institutes, endocrinology specialists, and specialty prescription patients globally. Amylyx Pharmaceuticals holds an established position in the biopharmaceutical sector for neurodegenerative disease therapeutic research. The corporation is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.

6 of the funds FundTelligence covers report a position in Amylyx Pharmaceuticals.

Legal name
Amylyx Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
6

Funds holding Amylyx Pharmaceuticals

Loading...